{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:10:48Z","timestamp":1793833848222,"version":"4.6.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.neurol.2018.01.368","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T19:10:06Z","timestamp":1523905806000},"page":"378-390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Classification and diagnostic criteria for demyelinating diseases of the central nervous system: Where do we stand today?"],"prefix":"10.1016","volume":"174","author":[{"given":"G.","family":"Mathey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pittion-Vouyovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Debouverie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2018.01.368_bib0365","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2018.01.368_bib0370","series-title":"Le\u00e7ons sur les maladies du syst\u00e8me nerveux recueilles et publi\u00e9es par Bourneville. vol. Tomes 1 et 2","author":"Charcot","year":"1887"},{"key":"10.1016\/j.neurol.2018.01.368_bib0375","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/WCO.0000000000000328","article-title":"Demyelinating diseases in Asia","volume":"29","author":"Ochi","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0380","first-page":"135","article-title":"Some aspects of the natural history of disseminated sclerosis","volume":"21","author":"McALPINE","year":"1952","journal-title":"Q J Med"},{"key":"10.1016\/j.neurol.2018.01.368_bib0385","series-title":"Multiple sclerosis","author":"McAlpine","year":"1955"},{"key":"10.1016\/j.neurol.2018.01.368_bib0390","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0395","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/WNL.0000000000001094","article-title":"Relapses and disability accumulation in progressive multiple sclerosis","volume":"84","author":"Paz Sold\u00e1n","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0400","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0405","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2018.01.368_bib0410","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0415","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0420","first-page":"1","article-title":"Prevalence of disseminated sclerosis in Northern Ireland","volume":"23","author":"Allison","year":"1954","journal-title":"Ulster Med J"},{"key":"10.1016\/j.neurol.2018.01.368_bib0425","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","article-title":"Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis","volume":"122","author":"Schumacher","year":"1965","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.neurol.2018.01.368_bib0430","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0435","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.msard.2011.08.002","article-title":"The diagnostic criteria for multiple sclerosis: from Charcot to McDonald","volume":"1","author":"Gafson","year":"2012","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2018.01.368_bib0440","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group","volume":"343","author":"Jacobs","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2018.01.368_bib0445","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study","volume":"357","author":"Comi","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2018.01.368_bib0450","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","article-title":"Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes","volume":"67","author":"Kappos","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0455","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet"},{"issue":"Pt 11","key":"10.1016\/j.neurol.2018.01.368_bib0460","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/brain\/120.11.2059","article-title":"Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis","volume":"120","author":"Barkhof","year":"1997","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0465","first-page":"702","article-title":"Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis","volume":"21","author":"Tintor\u00e9","year":"2000","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0470","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria.\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0475","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0480","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(07)70176-X","article-title":"MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study","volume":"6","author":"Swanton","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0485","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/archneurol.2009.49","article-title":"A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis","volume":"66","author":"Rovira","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0490","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.0b013e3181cec45c","article-title":"MRI criteria for MS in patients with clinically isolated syndromes","volume":"74","author":"Montalban","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0495","series-title":"2017 proposed revisions to the McDonald diagnostic criteria for multiple sclerosis","author":"Cohen","year":"2017"},{"key":"10.1016\/j.neurol.2018.01.368_bib0500","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","author":"Thompson","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0505","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1212\/WNL.0000000000002975","article-title":"Should the symptomatic region be included in dissemination in space in MRI criteria for MS?","volume":"87","author":"Brownlee","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0510","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1212\/WNL.0000000000003144","article-title":"Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis","volume":"87","author":"Tintore","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0515","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","article-title":"MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines","volume":"15","author":"Filippi","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0520","series-title":"Impact of including optic nerve lesions in dissemination in space in diagnostic criteria for multiple sclerosis","author":"Brownlee","year":"2017"},{"key":"10.1016\/j.neurol.2018.01.368_bib0525","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/brain\/awv105","article-title":"Defining high, medium and low impact prognostic factors for developing multiple sclerosis","volume":"138","author":"Tintore","year":"2015","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0530","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/1352458514568827","article-title":"Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study","volume":"21","author":"Kuhle","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2018.01.368_bib0535","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00415-016-8302-1","article-title":"Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome","volume":"263","author":"Huss","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0540","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jns.2017.06.008","article-title":"High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline","volume":"379","author":"Gaetani","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2018.01.368_bib0545","series-title":"The added value of oligoclonal bands in the multiple diagnostic criteria","author":"Arrambide","year":"2017"},{"key":"10.1016\/j.neurol.2018.01.368_bib0550","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/1352458512464829","article-title":"A proposed modification to the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis","volume":"19","author":"Kelly","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2018.01.368_bib0555","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ana.23575","article-title":"2010 McDonald criteria for diagnosing pediatric multiple sclerosis","volume":"72","author":"Sadaka","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0560","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1212\/01.wnl.0000259422.44235.a8","article-title":"Consensus definitions proposed for pediatric multiple sclerosis and related disorders","volume":"68","author":"Krupp","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0565","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2018.01.368_bib0570","article-title":"Application of the McDonald criteria in Latin America","volume":"3","author":"Patrucco","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.neurol.2018.01.368_bib0575","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/1352458513496881","article-title":"Evaluation of McDonald MRI criteria for dissemination in space in Korean patients with clinically isolated syndromes","volume":"20","author":"Huh","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2018.01.368_bib0580","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jns.2013.03.018","article-title":"Comparison of the 2010 and 2005 versions of the McDonald MRI criteria for dissemination-in-time in Taiwanese patients with classic multiple sclerosis","volume":"329","author":"Hsueh","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2018.01.368_bib0585","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1185\/03007995.2015.1047750","article-title":"Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS)","volume":"31","author":"Yamout","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.neurol.2018.01.368_bib0590","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/01.wnl.0000335764.14513.1a","article-title":"Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome","volume":"72","author":"Okuda","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0595","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archneurol.2009.119","article-title":"Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients","volume":"66","author":"Lebrun","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0600","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ana.24564","article-title":"Primary progressive multiple sclerosis evolving from radiologically isolated syndrome","volume":"79","author":"Kantarci","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0605","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/1352458512471874","article-title":"Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients","volume":"19","author":"Liu","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2018.01.368_bib0610","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.neurol.2018.01.368_bib0615","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2018.01.368_bib0620","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0625","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0630","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1212\/WNL.0b013e31824f8069","article-title":"Clinical spectrum of CNS aquaporin-4 autoimmunity","volume":"78","author":"Kim","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0635","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2018.01.368_bib0640","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1212\/WNL.0b013e3182343377","article-title":"Syndrome of inappropriate antidiuresis may herald or accompany neuromyelitis optica","volume":"77","author":"Iorio","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0645","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"Weinshenker","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0650","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0655","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0660","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/WNL.0000000000002655","article-title":"Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder","volume":"86","author":"Hyun","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0665","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1352458516663853","article-title":"The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates","volume":"23","author":"Hamid","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2018.01.368_bib0670","series-title":"Comparative evaluation of successive criteria for neuromyelitis optica","author":"Marignier","year":"2017"},{"key":"10.1016\/j.neurol.2018.01.368_bib0675","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0680","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event","volume":"349","author":"Berger","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2018.01.368_bib0685","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2018.01.368_bib0690","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0695","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1474-4422(11)70250-2","article-title":"MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study","volume":"10","author":"Verhey","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0700","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/01.wnl.0000338630.20412.45","article-title":"Role of MRI in the differentiation of ADEM from MS in children","volume":"72","author":"Callen","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.368_bib0705","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00415-015-7694-7","article-title":"Acute disseminated encephalomyelitis: current controversies in diagnosis and outcome","volume":"262","author":"Koelman","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0710","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/brain\/awq164","article-title":"Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)","volume":"133","author":"Pittock","year":"2010","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0715","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/brain\/awx200","article-title":"Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)","volume":"140","author":"Tobin","year":"2017","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2018.01.368_bib0720","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jnnp-2011-301054","article-title":"Expanding the clinical, radiological and neuropathological phenotype of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)","volume":"83","author":"Simon","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378717308536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378717308536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T04:29:29Z","timestamp":1635481769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378717308536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0035378717308536"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2018.01.368","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classification and diagnostic criteria for demyelinating diseases of the central nervous system: Where do we stand today?","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2018.01.368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}